Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liposomal Irinotecan-based Regimen Versus Irinotecan-based Regimen in Second-Line Treatment for Metastatic Colorectal Cancer (IRIS-02): A Randomized, Controlled Phase II/Ⅲ Study

NCT07585279 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT07585279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07585279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liposomal Irinotecan-based Regimen Versus Irinotecan-based Regimen in Second-Line Treatment for Metastatic Colorectal Cancer (IRIS-02): A Randomized, Controlled Phase II/Ⅲ Study
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
May 20, 2026
Completion date
February 28, 2032
Enrollment
408 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liposomal irinotecan, metastatic colorectal cancer (crc), second-line